Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10969404 | Vaccine | 2012 | 12 Pages |
Abstract
⺠A first-in-human study of a bivalent rLP2086 N. meningitidis serogroup B vaccine. ⺠Healthy adults received placebo or ascending dose levels of bivalent rLP2086. ⺠Bivalent rLP2086 induced robust serum bactericidal activity against 6 diverse MnB strains. ⺠Most recipients (75-100%) of 60 μg or 200 μg doses had seroprotective (â¥1:4) hSBA titres. ⺠The vaccine was well tolerated; adverse events were rare and generally mild or moderate.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
P.C. Richmond, M.D. Nissen, H.S. Marshall, S.B. Lambert, D. Roberton, W.C. Gruber, T.R. Jones, A. Arora,